William Bellamy - Concepedia

Author

William Bellamy

Also Known As

W BELLAMY, W Bellamy, W T Bellamy, W. Bellamy, W. T. Bellamy, WILLIAM BELLAMY, William Bellamy, William T Bellamy, William T. Bellamy

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

University of Arizona University of Arkansas for Medical Sciences Arizona Oncology University of Amsterdam Arizona Cancer Therapeutics (United States)

About

William Bellamy is an author at University of Arizona specializing in medicine, immunology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	26	3.1K
2	Health Sciences	10	10	1.1K
3	Engineering	4	4	121
4	Biochemistry	3	3	225
5	Natural Sciences	1	1	41

William Bellamy

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma Christina M. Annunziata, R. Eric Davis, Yulia N. Demchenko, Cancer Cell Hematological MalignancyTumor BiologyAlternative Nf-κb PathwaysFrequent EngagementImmune Cell Development	2007	929
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. William Bellamy, L Richter, Y Frutiger, PubMed Hematopoietic MalignanciesHuman VegfAngiogenesisVegf MessageImmunology	1999	531
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Sarah J. Welsh, William Bellamy, Margaret M. Briehl, PubMed Trx-1 TransfectionImmunologyCell DeathRedox BiologyRedox Protein	2002	348
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes William Bellamy, Lynne Richter, Davuud Sirjani, Blood	2001	338
Thioredoxin, a putative oncogene product,is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival Thomas M. Grogan, Cecilia Fenoglio-Prieser, R Zeheb, Human Pathology Tumor BiologyIncreased ProliferationOncogenic AgentMedicineImmunology	2000	189
Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients Susann Szmania, Natalia Lapteva, Tarun K. Garg, Journal of Immunotherapy Cell TherapyImmunologyImmunoeditingCell Replacement TherapyImmunotherapeutics	2014	179
pH and drug resistance. I. functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines Raul Martı́nez–Zaguilán, Natarajan Raghunand, Ronald M. Lynch, Biochemical Pharmacology Breast OncologyI. Functional ExpressionBiochemistryMedicineBreast Cancer	1999	144
Development and characterization of a melphalan-resistant human multiple myeloma cell line. William Bellamy, William S. Dalton, Mary C. Gleason, PubMed Hematological MalignancyDna Interstrand Cross-linkingHealth SciencesMedicineMalignant Blood Disorder	1991	126
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy Tarun K. Garg, Susann Szmania, Junaid Khan, Haematologica	2012	107
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108 Alison Stopeck, Joseph M. Unger, Lisa M. Rimsza, Leukemia & lymphoma/Leukemia and lymphoma	2009	104

Page 1